Understanding Patient Preferences for PARP Inhibitors in Ovarian Cancer
Patient Preferences for Precision Medicine
This study is trying to understand what women with ovarian cancer think about using a specific type of medication called PARP inhibitors to help them after chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Sex | Female |
| Sponsor | University of Saskatchewan Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Saskatoon, S) |
| Trial ID | NCT06751303 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with ovarian cancer who have defective DNA repair mechanisms and examines their preferences for maintenance therapy using PARP inhibitors (PARPi). It involves performing HRD testing to personalize treatment options based on the patients' responses to platinum-based chemotherapy. The study aims to evaluate treatment outcomes and quality of life in a real-world setting, providing insights into the efficacy and cost-effectiveness of PARPi therapy, particularly niraparib. By utilizing decision aids, the study seeks to empower patients in their treatment choices.
Who should consider this trial
Good fit: Ideal candidates include patients with known or suspected stage 3/4 high grade serous or endometrioid ovarian cancer who can provide consent and complete questionnaires in English.
Not a fit: Patients who are ineligible for maintenance PARPi therapy or refuse HRD testing may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for ovarian cancer patients, improving their quality of life.
How similar studies have performed: Other studies have shown promise in using HRD testing to guide PARPi therapy, indicating that this approach has potential based on previous findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Known or suspected stage 3/4 high grade serous or endometrioid ovarian cancer Able to provide oral consent and complete questionnaires in English as per study protocol Exclusion Criteria: * Ineligible for Maintenace PARPi therapy Refusal to undergo HRD testing
Where this trial is running
Saskatoon, S
- Saskatchewan Cancer Center — Saskatoon, S, Canada (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.